Financhill
Sell
35

TAK Quote, Financials, Valuation and Earnings

Last price:
$13.10
Seasonality move :
6.06%
Day range:
$13.02 - $13.19
52-week range:
$12.58 - $15.08
Dividend yield:
4.72%
P/E ratio:
21.67x
P/S ratio:
1.38x
P/B ratio:
0.86x
Volume:
1.8M
Avg. volume:
1.8M
1-year change:
-4.31%
Market cap:
$41.5B
Revenue:
$29.5B
EPS (TTM):
$0.60

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
TAK
Takeda Pharmaceutical
$7.2B -- 0.1% -- $16.03
ALPMY
Astellas Pharma
-- -- -- -- --
HCM
HUTCHMED (China)
-- -- -- -- $28.11
HLOSF
Healios KK
-- -- -- -- --
PPTDF
PeptiDream
-- -- -- -- --
SOLTF
Nxera Pharma
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
TAK
Takeda Pharmaceutical
$13.10 $16.03 $41.5B 21.67x $0.33 4.72% 1.38x
ALPMY
Astellas Pharma
$9.79 -- $17.5B 167.87x $0.25 4.81% 1.55x
HCM
HUTCHMED (China)
$14.31 $28.11 $2.4B 30.00x $0.00 0% 5.94x
HLOSF
Healios KK
$1.35 -- $121.7M -- $0.00 0% 32.00x
PPTDF
PeptiDream
$17.15 -- $2.2B 20.38x $0.00 0% 7.14x
SOLTF
Nxera Pharma
$6.16 -- $553.6M -- $0.00 0% 2.79x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
TAK
Takeda Pharmaceutical
42.19% 0.312 78.44% 0.68x
ALPMY
Astellas Pharma
36.57% -0.037 -- 0.71x
HCM
HUTCHMED (China)
9.99% -0.098 2.79% 2.39x
HLOSF
Healios KK
65.07% -0.707 34.39% 1.33x
PPTDF
PeptiDream
25.75% -2.667 6.45% 3.28x
SOLTF
Nxera Pharma
48.92% 1.984 55.24% 3.73x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
TAK
Takeda Pharmaceutical
$5.3B $1.8B 2.37% 4.01% 15.97% $1.3B
ALPMY
Astellas Pharma
$2.5B $306.7M 0.66% 0.97% 11.62% $366.7M
HCM
HUTCHMED (China)
-- -- -5.04% -5.49% -- --
HLOSF
Healios KK
$2.8M -$1.8M -55.94% -137.21% -24.5% -$4.8M
PPTDF
PeptiDream
$17.4M -$854.5K 24.02% 34.66% -1.5% $173.8M
SOLTF
Nxera Pharma
$48.9M $5.4M -2.75% -5.58% 11.44% $10.3M

Takeda Pharmaceutical vs. Competitors

  • Which has Higher Returns TAK or ALPMY?

    Astellas Pharma has a net margin of 7.83% compared to Takeda Pharmaceutical's net margin of 7.95%. Takeda Pharmaceutical's return on equity of 4.01% beat Astellas Pharma's return on equity of 0.97%.

    Company Gross Margin Earnings Per Share Invested Capital
    TAK
    Takeda Pharmaceutical
    66.47% $0.19 $83.8B
    ALPMY
    Astellas Pharma
    80.74% $0.13 $16.6B
  • What do Analysts Say About TAK or ALPMY?

    Takeda Pharmaceutical has a consensus price target of $16.03, signalling upside risk potential of 22.35%. On the other hand Astellas Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than Astellas Pharma, analysts believe Takeda Pharmaceutical is more attractive than Astellas Pharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    TAK
    Takeda Pharmaceutical
    3 1 0
    ALPMY
    Astellas Pharma
    0 0 0
  • Is TAK or ALPMY More Risky?

    Takeda Pharmaceutical has a beta of 0.498, which suggesting that the stock is 50.209% less volatile than S&P 500. In comparison Astellas Pharma has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.161%.

  • Which is a Better Dividend Stock TAK or ALPMY?

    Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.72%. Astellas Pharma offers a yield of 4.81% to investors and pays a quarterly dividend of $0.25 per share. Takeda Pharmaceutical pays 199.34% of its earnings as a dividend. Astellas Pharma pays out 684.38% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios TAK or ALPMY?

    Takeda Pharmaceutical quarterly revenues are $7.9B, which are larger than Astellas Pharma quarterly revenues of $3B. Takeda Pharmaceutical's net income of $619.7M is higher than Astellas Pharma's net income of $241.2M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 21.67x while Astellas Pharma's PE ratio is 167.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.38x versus 1.55x for Astellas Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TAK
    Takeda Pharmaceutical
    1.38x 21.67x $7.9B $619.7M
    ALPMY
    Astellas Pharma
    1.55x 167.87x $3B $241.2M
  • Which has Higher Returns TAK or HCM?

    HUTCHMED (China) has a net margin of 7.83% compared to Takeda Pharmaceutical's net margin of --. Takeda Pharmaceutical's return on equity of 4.01% beat HUTCHMED (China)'s return on equity of -5.49%.

    Company Gross Margin Earnings Per Share Invested Capital
    TAK
    Takeda Pharmaceutical
    66.47% $0.19 $83.8B
    HCM
    HUTCHMED (China)
    -- -- $834.1M
  • What do Analysts Say About TAK or HCM?

    Takeda Pharmaceutical has a consensus price target of $16.03, signalling upside risk potential of 22.35%. On the other hand HUTCHMED (China) has an analysts' consensus of $28.11 which suggests that it could grow by 96.4%. Given that HUTCHMED (China) has higher upside potential than Takeda Pharmaceutical, analysts believe HUTCHMED (China) is more attractive than Takeda Pharmaceutical.

    Company Buy Ratings Hold Ratings Sell Ratings
    TAK
    Takeda Pharmaceutical
    3 1 0
    HCM
    HUTCHMED (China)
    9 2 0
  • Is TAK or HCM More Risky?

    Takeda Pharmaceutical has a beta of 0.498, which suggesting that the stock is 50.209% less volatile than S&P 500. In comparison HUTCHMED (China) has a beta of 0.781, suggesting its less volatile than the S&P 500 by 21.86%.

  • Which is a Better Dividend Stock TAK or HCM?

    Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.72%. HUTCHMED (China) offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 199.34% of its earnings as a dividend. HUTCHMED (China) pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TAK or HCM?

    Takeda Pharmaceutical quarterly revenues are $7.9B, which are larger than HUTCHMED (China) quarterly revenues of --. Takeda Pharmaceutical's net income of $619.7M is higher than HUTCHMED (China)'s net income of --. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 21.67x while HUTCHMED (China)'s PE ratio is 30.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.38x versus 5.94x for HUTCHMED (China). Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TAK
    Takeda Pharmaceutical
    1.38x 21.67x $7.9B $619.7M
    HCM
    HUTCHMED (China)
    5.94x 30.00x -- --
  • Which has Higher Returns TAK or HLOSF?

    Healios KK has a net margin of 7.83% compared to Takeda Pharmaceutical's net margin of -107.23%. Takeda Pharmaceutical's return on equity of 4.01% beat Healios KK's return on equity of -137.21%.

    Company Gross Margin Earnings Per Share Invested Capital
    TAK
    Takeda Pharmaceutical
    66.47% $0.19 $83.8B
    HLOSF
    Healios KK
    86.35% -$0.04 $57.8M
  • What do Analysts Say About TAK or HLOSF?

    Takeda Pharmaceutical has a consensus price target of $16.03, signalling upside risk potential of 22.35%. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than Healios KK, analysts believe Takeda Pharmaceutical is more attractive than Healios KK.

    Company Buy Ratings Hold Ratings Sell Ratings
    TAK
    Takeda Pharmaceutical
    3 1 0
    HLOSF
    Healios KK
    0 0 0
  • Is TAK or HLOSF More Risky?

    Takeda Pharmaceutical has a beta of 0.498, which suggesting that the stock is 50.209% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock TAK or HLOSF?

    Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.72%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 199.34% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TAK or HLOSF?

    Takeda Pharmaceutical quarterly revenues are $7.9B, which are larger than Healios KK quarterly revenues of $3.2M. Takeda Pharmaceutical's net income of $619.7M is higher than Healios KK's net income of -$3.4M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 21.67x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.38x versus 32.00x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TAK
    Takeda Pharmaceutical
    1.38x 21.67x $7.9B $619.7M
    HLOSF
    Healios KK
    32.00x -- $3.2M -$3.4M
  • Which has Higher Returns TAK or PPTDF?

    PeptiDream has a net margin of 7.83% compared to Takeda Pharmaceutical's net margin of -5.57%. Takeda Pharmaceutical's return on equity of 4.01% beat PeptiDream's return on equity of 34.66%.

    Company Gross Margin Earnings Per Share Invested Capital
    TAK
    Takeda Pharmaceutical
    66.47% $0.19 $83.8B
    PPTDF
    PeptiDream
    47.13% -$0.02 $551.4M
  • What do Analysts Say About TAK or PPTDF?

    Takeda Pharmaceutical has a consensus price target of $16.03, signalling upside risk potential of 22.35%. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than PeptiDream, analysts believe Takeda Pharmaceutical is more attractive than PeptiDream.

    Company Buy Ratings Hold Ratings Sell Ratings
    TAK
    Takeda Pharmaceutical
    3 1 0
    PPTDF
    PeptiDream
    0 0 0
  • Is TAK or PPTDF More Risky?

    Takeda Pharmaceutical has a beta of 0.498, which suggesting that the stock is 50.209% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.826, suggesting its less volatile than the S&P 500 by 17.389%.

  • Which is a Better Dividend Stock TAK or PPTDF?

    Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.72%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 199.34% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TAK or PPTDF?

    Takeda Pharmaceutical quarterly revenues are $7.9B, which are larger than PeptiDream quarterly revenues of $36.8M. Takeda Pharmaceutical's net income of $619.7M is higher than PeptiDream's net income of -$2.1M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 21.67x while PeptiDream's PE ratio is 20.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.38x versus 7.14x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TAK
    Takeda Pharmaceutical
    1.38x 21.67x $7.9B $619.7M
    PPTDF
    PeptiDream
    7.14x 20.38x $36.8M -$2.1M
  • Which has Higher Returns TAK or SOLTF?

    Nxera Pharma has a net margin of 7.83% compared to Takeda Pharmaceutical's net margin of 12.96%. Takeda Pharmaceutical's return on equity of 4.01% beat Nxera Pharma's return on equity of -5.58%.

    Company Gross Margin Earnings Per Share Invested Capital
    TAK
    Takeda Pharmaceutical
    66.47% $0.19 $83.8B
    SOLTF
    Nxera Pharma
    78.44% $0.09 $928.9M
  • What do Analysts Say About TAK or SOLTF?

    Takeda Pharmaceutical has a consensus price target of $16.03, signalling upside risk potential of 22.35%. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than Nxera Pharma, analysts believe Takeda Pharmaceutical is more attractive than Nxera Pharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    TAK
    Takeda Pharmaceutical
    3 1 0
    SOLTF
    Nxera Pharma
    0 0 0
  • Is TAK or SOLTF More Risky?

    Takeda Pharmaceutical has a beta of 0.498, which suggesting that the stock is 50.209% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.337, suggesting its less volatile than the S&P 500 by 66.345%.

  • Which is a Better Dividend Stock TAK or SOLTF?

    Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.72%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 199.34% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TAK or SOLTF?

    Takeda Pharmaceutical quarterly revenues are $7.9B, which are larger than Nxera Pharma quarterly revenues of $62.4M. Takeda Pharmaceutical's net income of $619.7M is higher than Nxera Pharma's net income of $8.1M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 21.67x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.38x versus 2.79x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TAK
    Takeda Pharmaceutical
    1.38x 21.67x $7.9B $619.7M
    SOLTF
    Nxera Pharma
    2.79x -- $62.4M $8.1M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Will Iovance Biotherapeutics Stock Bounce Back?
Will Iovance Biotherapeutics Stock Bounce Back?

Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 21

Quantum [QMCO] is up 26.28% over the past day.

Sell
46
NUKK alert for Dec 21

Nukkleus [NUKK] is down 22.94% over the past day.

Sell
1
IIPR alert for Dec 21

Innovative Industrial Properties [IIPR] is down 22.7% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock